使用多式变压器识别进展特异性阿尔茨海默氏症亚型
Diego Machado Reyes1, Hanqing Chao1, Juergen Hahn1
1Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Journal of personalized medicine
|April 27, 2024
概括
早期识别阿尔茨海默病 (AD) 亚型至关重要. 一个新的多式模式框架,Tri-COAT,使用成像,遗传学和临床数据进行早期的,可解释的AD进展亚型分类.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 生物医学数据科学 生物医学数据科学
- 计算神经科学是一种神经科学.
背景情况:
- 阿尔茨海默病 (AD) 是最常见的神经退行性疾病,但目前的治疗方法有限,由于疾病异质性,其疗效尚不确定.
- 早期识别AD亚型对于有效干预至关重要,但在无症状或前期阶段预测这些是具有挑战性的.
- 现有的分类模型往往缺乏可解释性,依赖于单个数据模式,限制了它们的预测能力.
研究的目的:
- 开发和验证用于早期分类阿尔茨海默病进展亚型的多式联络框架.
- 引入三模共同注意力机制 (Tri-COAT) 来捕捉跨模特征关联.
- 为了提高AD亚型分类模型的可解释性.
主要方法:
- 开发了一个综合神经成像,遗传和临床评估数据的多式模式框架.
- 一个新的三模共同注意力机制 (Tri-COAT) 被引入,以模拟跨模特特征依赖.
- 该框架是根据阿尔茨海默病神经成像计划 (ADNI) 的数据进行训练和评估,使用十倍交叉验证.
主要成果:
- 与基线模型相比,Tri-COAT框架在分类AD进展亚型方面表现优越.
- 该模型在接收器操作特征曲线下实现了最高的分类区域.
- 共同注意力机制通过突出关键的跨模态特征关联,提供了可解释性.
结论:
- 拟议的多式联络框架有效地在早期阶段对阿尔茨海默病进展亚型进行分类.
- 通过利用成像,遗传学和临床数据的跨模式关联,Tri-COAT提供了一种可解释的方法.
- 这种方法对在阿尔茨海默病研究中推进个性化医学的前景充满希望.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


